N/A Completed N=18

Open Label Extension of LipoLat-CS202

Glaucoma

Source: ClinicalTrials.gov NCT02599688 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2020

Primary outcomePrimary: Intraocular Pressure (IOP) — -4.2 mm Hg

Summary

This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.

Outcome Measures

Outcome	Result	p-value
PRIMARY Intraocular Pressure (IOP)	-4.2	—

Eligibility Criteria

Inclusion criteria
Successful completion of 3 months of participation in Study LipoLat-CS202.
Treatment with POLAT-001 in Study LipoLat-CS202.
Able and willing to give signed informed consent and follow study instructions.
Exclusion criteria

Excluded from the study will be individuals with the following characteristics:

The development, during study LipoLat-CS202, of any exclusion criteria from that study (e.g., concomitant medication or co-morbid disease).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02599688). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.